{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-000028","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2022-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.240447+00:00","generated_at":"2026-06-27T20:54:50.576441+00:00","sec_items":["3.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aytu BioPharma appoints Mark Oki as CFO effective Jan 17, 2022; grants 100k inducement shares","bullets":["Mark Oki named CFO; annual base salary of $415,000, target bonus 40% of base, and $50,000 signing bonus.","Inducement award of 100,000 restricted shares granted under Nasdaq Rule 5635(c)(4), vesting over three years.","Severance: termination without cause or for good reason triggers base salary, COBRA for 12 months, and vesting.","Change-in-control provision: one times base salary plus target bonus, 12 months COBRA, full equity acceleration.","Oki previously CFO of Vivus and Alexza; brings over 20 years pharma finance experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-000028","json":"https://secwatch.observer/filing/0001558370-22-000028.json","markdown":"https://secwatch.observer/filing/0001558370-22-000028.md","text":"https://secwatch.observer/filing/0001558370-22-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022000028/0001558370-22-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022000028/aytu-20220104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:54:50.576441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64fdd44e5b","claim":"Mark Oki was appointed as Chief Financial Officer at AYTU BIOPHARMA, INC.","evidence_excerpt":"On January 4, 2022, Aytu issued a press release announcing the appointment of Mr. Oki as Chief Financial Officer of the Company effective January 17, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022000028/0001558370-22-000028-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}